Viagra-Style Pill Slows Alzheimer's Decline by 31% in Global Trial
A stage three trial across 13 countries found AR1001, a pill from the same drug family as Viagra, slowed cognitive decline by 31% in early Alzheimer's patients taking no other treatment. South Korean maker AriBio reported the results in Boston, though the benefit faded in patients already on other Alzheimer's drugs.
- Original source: theguardian.com.
- The source published it on Nov 18, 2026 at 5:00 AM.
- No second outlet has reported it yet. Treat it as a single-source claim.
A pill that works like Viagra on the brain's blood supply cut cognitive decline by 31% in people with early Alzheimer's disease who were taking no other treatment. South Korean drugmaker AriBio presented the stage three trial results at the Clinical Trials on Alzheimer's Disease conference in Boston, covering patients across 13 countries including the UK.
The drug, AR1001, is a phosphodiesterase-5 inhibitor, the same family of medicines as Viagra. AriBio said the decline slowed in 604 people who took AR1001 alone. In a broader group also taking other Alzheimer's drugs, the tablet failed to hit statistically significant results.
Prof Tara Spires-Jones of the University of Edinburgh called the results 'very promising', noting the drug boosts blood flow and likely stimulates brain pathways tied to learning and memory. Dr Sheona Scales of Alzheimer's Research UK said the findings marked 'an important milestone', and that AR1001 was 'especially interesting' because it acts on a specific enzyme rather than targeting amyloid like existing treatments.
Dr Richard Oakley of the Alzheimer's Society said the topline results were 'an exciting sign' of a possible 'totally new treatment' that tackles causes rather than symptoms, and highlighted its once-a-day tablet form as a simpler option. He flagged that the drug appeared less effective for people already on other Alzheimer's medications, something he said needs more study.
Oakley also drew a clear line on the Viagra comparison: AR1001 is being developed specifically for Alzheimer's, and people should not take Viagra to try to treat the disease. All the experts said further trials are needed, and the drug must clear scientific scrutiny and drug regulators before it can be prescribed.
There is still no cure for Alzheimer's, the most common form of dementia, which is forecast to affect 153 million people worldwide by 2050.
TopicsAriBio · AR1001 · Viagra · Tara Spires-Jones · Sheona Scales · Richard Oakley · Alzheimer's Research UK · Alzheimer's Society
Source: theguardian.com
Written by AI from verified reporting.
More stories
- Health & science theguardian.com 1 viewNHS staff snooped on patients' records 3,029 times in five years
- Health & science casrai.org 1 viewFDA Opens Its Review Files to Foreign Regulators, Starting With PEPFAR Drugs
- Health & science medicalxpress.com 1 viewFDA clears Sunharbo, first factor XIa inhibitor to prevent second strokes
- Health & science medicalxpress.com 1 viewFDA Approves Rybrevant Faspro for Advanced Head and Neck Cancer

